Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2223)	2/5/2008 3:25:13 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

IDMI Is up for 2nd Day on a roll, was up 75.43% at its previous intraday H of $2 at 11:45am & is now up 142% at its intraday H of $2.97 in the afternoon it was up 144.73%, in spite of the general market with volume now > 6.5M (the stock is up almost $1 as I was writing this note & should close near its H.) <g> bigcharts.marketwatch.com It has now closed its Aug 27 DG bigcharts.marketwatch.com It announced yesterday the results of its PIII L-MTP-PE, which showed impruved survival of children with ostosarcomas,reducing the risk of death by 30% The outlook of patients with osteosarcoma has remained poor.I remember about 20 years ago,while reviewing a series of patients treated at Miami's Jackson Memorial Hosp.,that the only case with a rather good survival after amputation & chemotherapy was that of a girl in which the amputation & chemo was delayed because the parent's religion (C.S.) & the amputation was carried out only after the tumor became infected & the child was having febrile episodes.Of course, it was not possible to try that same approach in future patients.<g> Liposomal muramyl tripeptide phosphatidylethanolamine or L-MTP-PE, MEPACT is a macrophage activator that completed a PIII as an additive therapy in 2005 for patients with newly diagnosed non-metastatic osteosarcoma. It is administered as an I.V. infusion 2x weekly for 12 weeks, & then 1x weekly for 24 weeks.In an unpublished PIII in newly diagnosed patients the company reported that L-MTP-PE significantly increased disease-free and overall survival. Developer, Immuno-Designed Molecules was granted orphan drug status in the EU in June 2004. Osteosarcoma is the most common type of primary bone cancer. Most cases occur in children and young people between the ages of 10 and 25. The overall 5-year survival of patients diagnosed in 1992 to 1996 was 57%. Patients with stage 1 disease have a 90% 5 Yr. survival. Patients with stage 2 disease (high grade and no spread) have a 55% 5 Yr. survival, and those with stage 3 disease (metastatic disease) a less than 10% 5 Yr. survival. In the PIII the most frequent adverse events were those typically associated with intensive chemo. In a PII in advanced soft tissue sarcoma 62% of 19 patients who received L-MTP-PE experienced a mild to moderate flu-like syndrome with fever, chills,myalgia and headache. These flu-like symptoms are considered to be signs of L-MTP-PE activity. There were no adverse haematological events. IDMI has been able to trim its losses significantly and consecutively in the last 4Qs & revenues also were somewhat better in the last 3Qs.The EL for 2007 is around $1.05 vs. the $1.75 loss in 2006 & for 2008 a further cut of the loss to around $0.85 is expected. The stock is trading around 2.8xBV with a negative CF around $1.65 The insiders hold around 20% of the shrs with little institutional following.The short ratio went up almost 20% & is around 2.5x its ADV. (There probably was a good amount of covering today.<g>) The next important resistance is the Jul 23 H at $2.85 & then the June 5 at $4.95(the May H at $10.75 seems a little far at present.<g>) bigcharts.marketwatch.com The March 2000 H was $149.58 <g> Bernard

To: Jibacoa who wrote (2223)	2/6/2008 4:27:36 PM
From: Jibacoa	Respond to of 3722

Well, if I remember how was the usual market's behavior in previous bear periods,the downside pressure was usually worse on Mondays & Tuesdays with some recovering in midweek & starting to decline again by late Fridays.<g> Today it seemed that things were going to start that same old pattern, but the up move didn't last until the end of the session, apparently because of some comments by the FED's Philadelphia President, Charles Plosser, who spoke against overly aggressive rate cuts. bigcharts.marketwatch.com But at least, the DOW closed above the 12,000 level & is still above its Jan 22 L of 11508 <g> bigcharts.marketwatch.com Now I guess will have to keep a close eye on what it will do the rest of the week.<g> A drop below the Jan 22 L could bring it to the 11,000 support level & as previously mentioned, if we get the same 39.73% "correction" from the Oct H of 14279 it would be a drop of 5673 points, or to the 8606 level, but if we get only a 30% "correction", then drop would be only of 4284 points from the Oct H to the 10000 level.<g> bigcharts.marketwatch.com Bernard